Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0024 | Chlorpromazine

Molecular Formula C17H19ClN2S
Molecular Weight 318.9
Structure
State liquid
Volume of distribution * 20 L/kg
Route of elimination Kidneys, ~ 37% excreted in urine
Protein binding > 90% to plasma proteins, primarily albumin
Half life ~ 30 hours
Absorption Readily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.
Description Antipsychotic; neuroleptics; prototypical phenothiazine antipsychotic drug; antiemetic;

N

N05AA01 Chlorpromazine


[N05AA] Phenothiazines with aliphatic side-chain


[N05A] ANTIPSYCHOTICS


[N05] PSYCHOLEPTICS


[N] Nervous system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
OPENING OF PERMEABILITY TRANSITION PORE (PTP) >100 µM 1 hour Human HepG2 High-content screening assay Affect MEC 306
ELECTROPHORETIC UNCOUPLING 278
MEMBRANE POTENTIAL 100 µM 1 hour Human HepG2 High-content screening assay Decrease MEC 306
STATE 3 RESPIRATION decrease 22
STATE 4 RESPIRATION increase 22
OXYGEN CONSUMPTION RATE (OCR) > 300 μM 2 minutes human HepG2 Measurement of OCR increase EC50 7
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity decrease p < 0.001 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity decrease p < 0.001 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex V activity decrease p < 0.001 3
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria decrease 23
ELECTRON TRANSPORT CHAIN decrease 7
ELECTRON TRANSPORT CHAIN inhibit 197
ECAR > 300 μM 2 minutes human HepG2 Measurement of ECAR increase EC50 7
GLUCOSE GALACTOSE IC50 RATIO 36.6 ± 19.4, 48.4 ± 11.9, 0.8, 17.3 ± 7.6, 25.3 ± 10.8, 0.7 4hr H9c2 cells high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) 50
POTASSIUM RELEASE increase 22
ROS PRODUCTION 50 µM 1 hour Human HepG2 High-content screening assay Increase MEC 306

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
NADH:ubiquinone reductase rat isolated liver mitochondria inhibitor 23
NADH:ubiquinone reductase inhibitor 7
Succinate dehydrogenase 50 μM bovine heart mitochondria Measurement of complex II + III activity inhibitor p < 0.001 3
Quinol--cytochrome-c reductase 50 μM bovine heart mitochondria Measurement of complex II + III activity inhibitor p < 0.001 3
Cytochrome c oxidase 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ATP synthase 50 μM bovine heart mitochondria Measurement of complex V activity inhibitor p < 0.001 3
potassium not specified 22
Reactive oxygen species 50 µM 1 hour Human HepG2 High-content screening assay increase MEC 306

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]


H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]


H331 (100%): Toxic if inhaled [Danger Acute toxicity, inhalation]


H362 (100%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]


H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]


H410 (100%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P260, P261, P263, P264, P270, P271, P272, P273, P280, P301+P310, P302+P352, P304+P340, P308+P313, P311, P321, P330, P333+P313, P363, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 intraperitoneal > 2gm/kg (2000mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
monkey LD50 subcutaneous > 5mg/kg (5mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
rabbit LD50 intravenous 16mg/kg (16mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 120, Pg. 450, 1959.
rat LD50 intramuscular > 2gm/kg (2000mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
rabbit LD50 intravenous 5mg/kg (5mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 15, 1972.
mammal (species unspecified) LD50 oral 500mg/kg (500mg/kg) Journal of Medicinal Chemistry. Vol. 8, Pg. 836, 1965.
rat LD50 intravenous 243mg/kg (243mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
rat LD50 intraperitoneal 137mg/kg (137mg/kg) German Offenlegungsschrift Patent Document. Vol. #2350222,
guinea pig LD50 subcutaneous 420mg/kg (420mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 137, Pg. 375, 1962.
mouse LC50 inhalation 40mg/m3/2H (40mg/m3) "Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986Vol. -, Pg. 1106, 1986.
women TDLo oral 35gm/kg/16Y-I (35000mg/kg) Biological Psychiatry. Vol. 18, Pg. 1441, 1983.
mouse LD50 intramuscular > 2gm/kg (2000mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
rat LD50 subcutaneous 75mg/kg (75mg/kg) Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 56, Pg. 377, 1960.
guinea pig LD50 intraperitoneal 87mg/kg (87mg/kg) Medicina Experimentalis. Vol. 8, Pg. 237, 1963.
women TDLo oral 6mg/kg (6mg/kg) Postgraduate Medical Journal. Vol. 60, Pg. 564, 1984.
mouse LD50 intravenous 20mg/kg (20mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 808, 1971.
mouse LD50 intravenous 16mg/kg (16mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
mouse LD50 oral 135mg/kg (135mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 118, Pg. 358, 1959.
women TDLo oral 16800ug/kg/3W (16.8mg/kg) blood: agranulocytosis Postgraduate Medical Journal. Vol. 69, Pg. 885, 1993.
rat LD50 intravenous 25mg/kg (25mg/kg) Fortschritte der Arzneimittelforschung. Progress in Drug Research. Vol. 5, Pg. 269, 1963.
rat LD50 oral 145mg/kg (145mg/kg) Journal of Pharmacology and Experimental Therapeutics. Vol. 148, Pg. 151, 1965.
mouse LDLo intracrebral 2mg/kg (2mg/kg) behavioral: convulsions or effect on seizure threshold Planta Medica. Vol. 49, Pg. 103, 1983.
mouse LD50 subcutaneous 420mg/kg (420mg/kg) British Journal of Pharmacology and Chemotherapy. Vol. 22, Pg. 301, 1964.
chicken LD50 intravenous 28mg/kg (28mg/kg) Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960.
guinea pig LDLo oral 250mg/kg (250mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 561, 1976.
rat LC50 inhalation 40mg/m3/2H (40mg/m3) "Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986Vol. -, Pg. 1106, 1986.
guinea pig LD50 intraperitoneal 109mg/kg (109mg/kg) Pharmazie. Vol. 38, Pg. 749, 1983.
mouse LD50 oral 6257mg/kg (6257mg/kg) behavioral: excitement Archives Internationales de Pharmacodynamie et de Therapie. Vol. 125, Pg. 83, 1960.
women TDLo oral 240mg/kg/30D- (240mg/kg) Journal of Clinical Psychiatry. Vol. 46, Pg. 341, 1985.
guinea pig LD50 intraperitoneal 374mg/kg (374mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
monkey LDLo oral > 30mg/kg (30mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 122, Pg. 129, 1959.
mouse LD50 intraperitoneal 14mg/kg (14mg/kg) Farmaco, Edizione Scientifica. Vol. 14, Pg. 269, 1959.
mouse LD50 unreported 82500ug/kg (82.5mg/kg) Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 53, Pg. 2S, 1957.
rat LC50 inhalation 209mg/m3/2H (209mg/m3) Toksikologiya Novykh Promyshlennykh Khimicheskikh Veshchestv. Toxicology of New Industrial Chemical Substances. For English translation, see TNICS*. Vol. 10, Pg. 73, 1968.
dog LD50 intravenous 30mg/kg (30mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 118, Pg. 358, 1959.
rabbit LD50 oral 5848mg/kg (5848mg/kg) Antibiotics and Chemotherapy Vol. 10, Pg. 376, 1960.
man TDLo oral 217mg/kg/19D (217mg/kg) Journal of Clinical Psychiatry. Vol. 46, Pg. 341, 1985.
rat LD50 oral 142mg/kg (142mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 261, 1968.
women TDLo oral 200ug/kg (0.2mg/kg) New York State Journal of Medicine. Vol. 57, Pg. 1922, 1957.
infant TDLo oral 20mg/kg (20mg/kg) American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976.
child LDLo oral 37500ug/kg (37.5mg/kg) New England Journal of Medicine. Vol. 256, Pg. 527, 1957.
women TDLo oral 166mg/kg/18D- (166mg/kg) Postgraduate Medical Journal. Vol. 53, Pg. 278, 1977.
women TDLo oral 240mg/kg/30D (240mg/kg) Journal of Clinical Psychiatry. Vol. 46, Pg. 341, 1985.
man TDLo oral 8900ug/kg (8.9mg/kg) lungs, thorax, or respiration: dyspnea American Journal of Emergency Medicine. Vol. 14, Pg. 467, 1996.
women TDLo intravenous 822ug/kg (0.822mg/kg) Annals of Emergency Medicine. Vol. 17, Pg. 380, 1988.
cat LD50 subcutaneous > 10mg/kg (10mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
man TDLo intravenous 1786ug/kg/2D- (1.786mg/kg) Biological Psychiatry. Vol. 18, Pg. 1441, 1983.
rat LD50 intraperitoneal > 2gm/kg (2000mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
mouse LC50 inhalation 209mg/m3/2H (209mg/m3) Toksikologiya Novykh Promyshlennykh Khimicheskikh Veshchestv. Toxicology of New Industrial Chemical Substances. For English translation, see TNICS*. Vol. 10, Pg. 73, 1968.
chicken LD50 intraperitoneal 160mg/kg (160mg/kg) Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960.
rat LD50 oral 8900mg/kg (8900mg/kg) Antibiotics and Chemotherapy Vol. 12, Pg. 249, 1962.
guinea pig LD50 oral 382mg/kg (382mg/kg) Antibiotics and Chemotherapy Vol. 11, Pg. 276, 1961.
dog LDLo oral 250mg/kg (250mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 561, 1976.
mouse LDLo intramuscular 300mg/kg (300mg/kg) Therapie. Vol. 15, Pg. 1064, 1960.
mouse LD50 oral 135mg/kg (135mg/kg) Chemical and Pharmaceutical Bulletin. Vol. 24, Pg. 1179, 1976.
human TDLo oral 8570ug/kg/12D (8.57mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 93, 1972.
man TDLo oral 6071ug/kg (6.071mg/kg) Israel Journal of Medical Sciences. Vol. 5, Pg. 1254, 1969.
mouse LD50 subcutaneous 33mg/kg (33mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
rat LD50 intravenous 23mg/kg (23mg/kg) Farmaco, Edizione Pratica. Vol. 26, Pg. 585, 1971.
cat LDLo oral 100mg/kg (100mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 561, 1976.
dog LD50 subcutaneous > 20mg/kg (20mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
rat LD50 unreported 90mg/kg (90mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 15, 1972.
rat LD50 subcutaneous 11250mg/kg (11250mg/kg) gastrointestinal: "hypermotility, diarrhea" Toxicology and Applied Pharmacology. Vol. 9, Pg. 445, 1966.
mouse LD50 intraperitoneal 92200ug/kg (92.2mg/kg) Toxicology and Applied Pharmacology. Vol. 2, Pg. 558, 1960.
mouse LD50 intravenous 240mg/kg (240mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
guinea pig LD50 intravenous 303mg/kg (303mg/kg) Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 306, 1970.
rat LD50 intraperitoneal 62mg/kg (62mg/kg) Psychopharmacologia Vol. 12, Pg. 142, 1968.
guinea pig LD50 intramuscular 1180mg/kg (1180mg/kg) Antibiotics Annual. Vol. 3, Pg. 534, 1955/1956.
man TDLo oral 18mg/kg (18mg/kg) Israel Journal of Medical Sciences. Vol. 5, Pg. 1254, 1969.

  • Affect lability

  • Anxiety

  • Bipolar disorder

  • Bipolar I disorder

  • Conduct disorder

  • Disturbance in social behaviour

  • Electroencephalogram abnormal

  • Foetor hepaticus

  • Frustration

  • Hepatocellular injury

  • Hiccups

  • Hyperkinesia

  • Liver disorder

  • Mitral valve incompetence

  • Mood swings

  • Nausea

  • Porphyria acute

  • Psychotic disorder

  • Schizophrenia

  • Tetanus

  • Vomiting

    • (chloropromazine) [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine (chlorpromazine)[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine 10-(3-Dimethylaminopropyl)-2-chlorophenothiazine
    10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl- 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+) 1N,1N-dimethyl-3-(2-chloro-10H-10-phenothiazinyl)-1-propanamine
    2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine 2-Chloro-10-(3-dimethylaminopropyl)phenothiazine 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine
    2-Chloropromazine 2-Cloro-10 (3-dimetilaminopropil)fenotiazina 2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]
    2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine 2-chloro-10-[3-(dimethylamino)propyl]- 2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine
    2601-A 2601A 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
    3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine # 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
    3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine 34468-21-8 4560 R.P
    4560 R.P. 4560 Rp hydrochloride 50-53-3
    AB00051943 AB00051943-15 AB00051943-16
    AB00051943_17 AB00051943_18 AB0015094
    AKOS001490972 ALBB-022464 API0001970
    AX8120990 Aminasine Aminazin
    Aminazine Ampliactil Amplicitil
    Amplictil BBL028251 BC 135
    BCP03610 BDBM50001888 BPBio1_000273
    BPBio1_001181 BRD-K89997465-001-05-3 BSPBio_000247
    BSPBio_002011 Bio1_000457 Bio1_000946
    Bio1_001435 Biomol-NT_000020 C06906
    C17H19ClN2S CAS-50-53-3 CAS-69-09-0
    CCG-40059 CCRIS 3711 CHEBI:3647
    CHEMBL71 CPZ CTK1C5154
    Chlor-PZ Chlor-Promanyl Chlordelazin
    Chlordelazine Chlorderazin Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine
    Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French] Chloropromazine Chlorpromados
    Chlorpromazin Chlorpromazine (USP/INN) Chlorpromazine Tannate
    Chlorpromazine [USAN:INN:BAN] Chlorpromazine [USP:INN:BAN] Chlorpromazine cation radical
    Chlorpromazine;[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine Chlorpromazinum Chlorpromazinum [INN-Latin]
    Chlropromados Clorpromazina Clorpromazina [INN-Spanish]
    Clorpromazina [Italian] Contomin Cromedazine
    D00270 DB00477 DSSTox_CID_2808
    DSSTox_GSID_22808 DSSTox_RID_76736 DTXSID0022808
    DivK1c_000624 EINECS 200-045-8 Elmarin
    Epitope ID:136898 Esmind FT-0653683
    Fenactil Fenaktyl Fraction
    Fraction AB GG 407 GTPL83
    HL 5746 HMS1920M03 HMS2089C12
    HMS2091E06 HMS3430C19 HMS501P06
    HSDB 3033 Hibanil Hibernal (Salt/Mix)
    IDI1_000624 J10069 JHICC02042
    KBio1_000624 KBio2_000622 KBio2_002312
    KBio2_003190 KBio2_004880 KBio2_005758
    KBio2_007448 KBio3_001231 KBio3_002792
    KBioGR_000806 KBioGR_002312 KBioSS_000622
    KBioSS_002314 KS-00002WW5 KS-5101
    KSC-315-032- KUC112482N L000182
    LS-105361 Largactil Largactilothiazine
    Largactyl Lomazine (Salt/Mix) Lopac-C-8138
    Lopac0_000249 M-1209 M176
    MCULE-5976054678 MLS003166901 Megaphen
    N-(3-Dimethylaminopropyl)-3-chlorophenothiazine NCGC00015273-01 NCGC00015273-02
    NCGC00015273-03 NCGC00015273-04 NCGC00015273-05
    NCGC00015273-06 NCGC00015273-07 NCGC00015273-08
    NCGC00015273-09 NCGC00015273-10 NCGC00015273-11
    NCGC00015273-12 NCGC00015273-13 NCGC00015273-14
    NCGC00015273-15 NCGC00015273-16 NCGC00015273-17
    NCGC00015273-19 NCGC00024409-04 NCGC00024409-05
    NCGC00024409-06 NCGC00024409-07 NCGC00024409-08
    NINDS_000624 NSC 167745 NSC-167745
    NSC-756689 NSC167745 NSC17479
    NSC756689 Norcozine (Salt/Mix) Novomazina
    Oprea1_110255 Pharmakon1600-01500184 Phenactyl
    Phenathyl Phenothiazine hydrochloride Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-
    Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]- Plegomasine Prazilpromactil
    Prestwick0_000064 Prestwick1_000064 Prestwick2_000064
    Prestwick3_000064 Proma Promactil
    Promazil Propaphen Propaphenin
    Prozil Psychozine Q407972
    QSPL 401 QTL1_000021 R1242
    RP-4560 SBI-0050237.P004 SC-50091
    SCHEMBL8321 SKF 2601-A SKF 2601A
    SKF-2601 SMR001453710 SPBio_001111
    SPBio_002168 SPECTRUM1500184 SR-01000000012-5
    SR-01000000012-6 STK182870 Sanopron
    Spectrum2_001156 Spectrum3_000346 Spectrum4_000283
    Spectrum5_000717 Spectrum_000142 Thorazine
    Thorazine (TN) Thorazine Suppositories Thorazine hydrochloride
    Torazina Tox21_110120 Tox21_110120_1
    Tranzine (Salt/Mix) U42B7VYA4P UNII-U42B7VYA4P
    Unitensen WLN: T C666 BN ISJ B3N1&1 EG Wintermin
    Z80 ZINC44027 ZPEIMTDSQAKGNT-UHFFFAOYSA-N
    [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine (chlor-promazine) [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine( Chlorpromazine) [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine(clorpromazine)
    [3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine [3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine hydrochloride cMAP_000017
    chlorpromazine

    DrugBank Name Chlorpromazine
    DrugBank DB00477
    CAS Number 113-98-4, 146702-01-4, 34468-21-8, 50-53-3, 69-09-0
    PubChem Compound 2726
    KEGG Compound ID C06906
    KEGG Drug D00270
    PubChem.Substance 46508395
    ChEBI 3647
    PharmGKB PA448964
    ChemSpider 2625
    BindingDB 50001888.0
    TTD DAP000374
    Wikipedia Chlorpromazine
    HET Z80
    DPD 8017|20237

    1. Chan et al. (2005)
    2. Vuda et al. (2016)